Clinical Trial Update: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects [Phase 1]

View source ↗

Summary

A Phase 1 MAD (multiple ascending dose) study of PMG1015 in idiopathic pulmonary fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• PMG1015

Snippet

Sponsor: Pulmongene Ltd. | Conditions: IPF | Phase 1 | Status: COMPLETED